Aptagen, LLC
DNA
Human Hepatocellular carcinoma cell line (LH86)
Cells
7.16 nM (reported value)
Binding buffer (PBS containing 5 mM MgCl2, 4.5 mg/mL glucose, 0.1 mg/mL yeast tRNA, 1 mg/mL BSA)
4°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Binds to hepatocellular carcinoma LH86 cell line. Negative control was normal liver cells, Hu1082.
Human Hepatocellular carcinoma (TLS11a) (ID# 286)
5'dApdCpdApdGpdCpdApdTpdCpdCpdCpdCpdApdTpdGpdTpdGpdApdApdCpdApdApdTpdCpdGpdCpdApdTpdTpdGpdTpdGpdApdTpdTpdGpdTpdTpdApdCpdGpdGpdTpdTpdTpdCpdCpdGpdCpdCpdTpdCpdApdTpdGpdGpdApdCpdGpdTpdGpdCpdTpdGp3'
63
19339.58 g/mole
589200 L/(mole·cm)
50.79%
1.70
32.82
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Meng, L. (2012). Targeted delivery of chemotherapy agents using liver cancer-specific aptamer. PloS One, 7(4), doi: 10.1371
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.